Flunisolide
From Wikipedia, the free encyclopedia
|
Flunisolide
|
|
| Systematic (IUPAC) name | |
| 6α-Fluoro-11β,16α,17,21- tetrahydroxypregna-1,4- diene-3,20-dione cyclic 16,17-acetal acetone | |
| Identifiers | |
| CAS number | |
| ATC code | R01 R03BA03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C24H31FO6 |
| Mol. mass | 434.498 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 40% after oral inhalation |
| Metabolism | ? |
| Half life | 1.8 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Inhaled |
Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid often prescribed as treatment for allergic rhinitis.
The principal mechanism of action of flunisolide is to activate glucocorticoid receptors. It also has anti-inflammatory action.
|
|||||||||||||||||

